InvestorsHub Logo
Post# of 253265
Next 10
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

Re: ghmm post# 208049

Monday, 01/16/2017 9:09:28 PM

Monday, January 16, 2017 9:09:28 PM

Post# of 253265
ACRS -

Well to alleviate some of your worries they already reported results.

LOL Yes, that alleviates some of the worries. Sorry, I took a quick look at the pipeline and it looked like something still in P3 with results yet to be reported. Understood on your other concerns.

yes I've heard other JAK's for Alopecia but I don't know where any of the programs stand. It seems they are working on both oral and Topical formulations which I find interesting. I own CLVLY which is developing a drug for amongst other things Vitiligo and have come across some findings that JAK's have potential here. Its a disease that really could use better options (a lot of unapproved things, makeup and light therapy seem to be what is used no approved drug).

I was mistaken as the small-cap Australian company I was thinking of is actually targeting FGF5. Name is Cellmid. I don't take seriously at all as they have 1B (!) shares O/S, trade at 2.5 cents/share, and have just positioned their drug as part of some OTC product.

On the JAK side, I assume any of the JAK players could potentially have interest in alopecia unless there is a specific niche needed (JAK1/2/or 3?). Also, interesting that it looks like ACRS is partnered with RIGL. I'm assuming they got their whole JAK pipe for alopecia from RIGL.

I have always thought of CLVLY as at least one of the more legit small-cap Australian biotechs but would need to do more DD to think about any possible position.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.